Palliative Chemotherapy
Palliative chemotherapy aims to improve quality of life, control symptoms, and extend survival in patients with incurable cancer, requiring careful balance of benefit against treatment toxicity.
Key Facts
Palliative chemotherapy aims to improve quality of life and extend survival; it is not curative Patient performance status (ECOG 0-2) is the most important factor determining suitability for palliative chemo Median survival benefit varies widely: weeks to months depending on cancer type and regimen Quality of life assessment should be integral to treatment decisions; validated tools include EORTC QLQ-C30 Treatment breaks/holidays are appropriate and increasingly recognised as valuable for patients Shared decision-making is essential: patients must understand treatment intent, expected benefits, and side effects NICE recommends against chemotherapy in patients with ECOG PS ≥3 (limited benefit, high toxicity risk) Advance care planning should be discussed alongside palliative chemotherapy decisions
Overview
Key Facts
Palliative chemotherapy is a cornerstone of cancer care but requires careful patient selection and honest communication about goals and limitations.
Epidemiology
- Approximately 50% of chemotherapy given in the UK is with palliative intent
- Treatment-related mortality from palliative chemo: approximately 2-3%
- SACT 30-day mortality is a national quality indicator (target <8%)
Aetiology
Palliative chemotherapy is indicated for incurable/metastatic cancers where treatment may improve symptoms and extend life.
Pathophysiology
- Same mechanisms as curative chemotherapy (DNA damage, cell cycle disruption)
- Lower dose intensities and less aggressive regimens may be used to balance efficacy and toxicity
- Treatment breaks allow recovery and maintain quality of life
- Immunotherapy and targeted therapies increasingly used in the palliative setting with potentially fewer side effects than cytotoxic chemotherapy
Clinical Presentation
Indications for Palliative Chemotherapy
- Symptom control (e.g. pain from tumour, dyspnoea, bleeding)
- Disease control (slow progression, prevent complications)
- Survival extension
- Patient preference (desire to "do something")
Assessment Before Treatment
- Performance status (ECOG 0-2 generally required)
- Organ function (renal, hepatic, cardiac, bone marrow)
- Nutritional status
- Patient understanding and expectations
- Goals of care discussion
Red Flags Indicating Treatment May Not Be Appropriate
- ECOG PS ≥3
- Severe organ dysfunction
- Recent acute illness or infection
- Patient ambivalence or lack of understanding about palliative intent
- Rapidly deteriorating condition
- Less than 3 months predicted survival (for most regimens)
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| Treatment toxicity | Side effects mimicking disease progression | Clinical assessment, bloods |
| Disease progression | Rising markers, new symptoms, imaging progression | Restaging CT/PET |
| Concurrent illness | Infection, PE, cardiac event | Appropriate investigations |
| Depression/fatigue | May mimic poor performance status | Psychological assessment |
Diagnosis / Investigation
Bedside
- Performance status assessment (ECOG/Karnofsky)
- Weight, BMI, nutritional assessment
- Quality of life assessment (EORTC QLQ-C30)
Bloods
- FBC, U&Es, LFTs (organ function; assess before each cycle)
- GFR (for dose calculations, especially platinum agents)
- Tumour markers (monitoring response)
- Albumin (nutritional/prognostic marker)
Imaging
- Restaging CT typically every 3-4 cycles (RECIST criteria)
- Response: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)
Special Tests
- Quality of life questionnaires
- Holistic needs assessment
- DPYD testing before fluoropyrimidines
- Echocardiography if using cardiotoxic agents
Management
Non-pharmacological
- Shared decision-making: ensure patient understands palliative intent
- Goals of care discussions (what matters most to the patient)
- Advance care planning: discuss alongside treatment decisions
- Treatment breaks: acceptable and may improve quality of life without worsening outcomes
- Nutritional support
- Psychological support
- Palliative care involvement (not just at end of life)
Pharmacological
- Regimen selection based on: cancer type, molecular profile, performance status, comorbidities, patient preference
- Common palliative regimens: single-agent or reduced-intensity combinations
- Supportive care: antiemetics, G-CSF if indicated, growth factors
- Dose modifications based on toxicity
- Treatment duration: typically continued until progression or intolerable toxicity
Surgical/Interventional
- Not specifically related to palliative chemotherapy
- Palliative procedures may be used alongside (stenting, drainage, RT)
Referral Criteria
- All patients receiving palliative chemotherapy: regular oncology review
- Deteriorating performance status: reassess treatment appropriateness
- Palliative care referral: concurrent with palliative chemotherapy (early referral improves outcomes — Temel 2010 NEJM)
- Treatment toxicity: acute oncology assessment
Prognosis
- Varies enormously by cancer type and regimen:
- Metastatic CRC (FOLFOX + biological): median OS 25-30 months
- Metastatic NSCLC (immunotherapy): median OS 15-25 months
- Metastatic pancreatic (mFOLFIRINOX): median OS 11 months
- Benefit must be weighed against toxicity for each individual
- SACT 30-day mortality: approximately 3-8% depending on regimen
- Concurrent palliative care improves quality of life and may extend survival (Temel et al. 2010)
- Many patients overestimate the survival benefit of palliative chemotherapy
Other Relevant Information
ECOG Performance Status and Treatment Suitability
| ECOG | Description | Palliative Chemo Suitability |
|---|---|---|
| 0 | Fully active | Yes |
| 1 | Restricted strenuous activity | Yes |
| 2 | Ambulatory, self-caring, up >50% | Consider (reduced intensity) |
| 3 | Limited self-care, >50% in bed/chair | Generally not appropriate |
| 4 | Completely disabled | Not appropriate |
SACT 30-Day Mortality (NHS England Quality Indicator)
| Metric | Target |
|---|---|
| 30-day mortality after curative chemo | <1% |
| 30-day mortality after palliative chemo | <8% |
| Chemotherapy in last 30 days of life | Minimise (quality indicator) |